AP NEWS
Press release content from PR Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from PR Newswire
Press release content from PR Newswire. The AP news staff was not involved in its creation.

Pulmonary arterial hypertension treatment with macitentan is safe and effective for patients with systemic sclerosis

October 14, 2019
American College of Chest Physicians (PRNewsfoto/American College of Chest Physic)
American College of Chest Physicians (PRNewsfoto/American College of Chest Physic)

NEW ORLEANS, Oct. 14, 2019 /PRNewswire/ -- Patients with pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc) who were treated with macitentan had similar therapeutic and safety results as patients with PAH from both idiopathic PAH (IPAH) and heritable PAH (HPAH), which is caused by a genetic mutation that runs in families, according to Vallerie McLaughlin, MD, FCCP, from the University of Michigan, Ann Arbor, who will present the study findings at the CHEST Annual Meeting 2019 in New Orleans.

Patients with PAH associated with connective tissue disease, including systemic sclerosis, are not expected to be as healthy as patients with other forms of PAH.

To evaluate macitentan’s impact on (PAH-SSc), the researchers used data from OPsumit USers (OPUS) Registry and OPsumit Historical USers cohort study (OrPHeUS), which provides medical information on patients with PAH who are newly started on macitentan. By October 2018, 659 patients with PAH-SSc had follow-up data in OPUS/OrPHeUS. The investigators compared these outcomes with those of 2,283 patients with IPAH and HPAH.

The researchers concluded: “In this real-world data set, the clinical outcomes and safety profile in patients with PAH-SSc are generally consistent with those of IPAH and HPAH patients. These data add to the body of evidence supporting the use of macitentan for the treatment of PAH-SSc.”

“Treatment with macitentan in this high-risk group of patients with pulmonary arterial hypertension with systemic sclerosis had similar outcomes compared with patients with idiopathic PAH,” explained Victor Test, MD, Co-Chair of the CHEST Scientific Program Committee and Professor of Texas Tech University Health Sciences Center. “This result is encouraging for this high-risk group in a real-world setting,” he stated.

MEETING
Further results from this study will be shared at CHEST Annual Meeting 2019 in New Orleans on Monday, Oct. 21, 1:30 p.m. to 2:30 p.m., at the Ernest N. Morial Convention Center, Room 288. The study abstracts can be viewed on the journal CHEST® website.

ABOUT CHEST 2019
CHEST 2019 is the 85th annual meeting for the American College of Chest Physicians held Oct. 19 to Oct. 23, 2019, in New Orleans. The American College of Chest Physicians, publisher of the journal CHEST®, is the global leader in advancing best patient outcomes through innovative chest medicine education, clinical research and team-based care. Its mission is to champion the prevention, diagnosis and treatment of chest diseases through education, communication and research. It serves as an essential connection to clinical knowledge and resources for its 19,000 members from around the world who provide patient care in pulmonary, critical care and sleep medicine. For more information about CHEST 2019, visit chestmeeting.chestnet.org, or follow CHEST meeting hashtag, #CHEST2019, on social media.

Media Contact:
Lisa Baer
lbaer@chestnet.org
(224) 521-9550

View original content to download multimedia: http://www.prnewswire.com/news-releases/pulmonary-arterial-hypertension-treatment-with-macitentan-is-safe-and-effective-for-patients-with-systemic-sclerosis-300937526.html

SOURCE American College of Chest Physicians